# MDxHealth SA (MDXH)

> Source: Nexqual · https://nexqual.com/MDXH · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, MDxHealth SA (MDXH), nexqual.com/MDXH" · informational, not investment advice.

**Price:** USD 0.6 (-4.45% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 0.63 · day 0.58–0.65 · 52w 0.4–5.33 · market cap $57.6M · NCM

## Key facts
- Analysts: Buy (mean 2.33 on a 1–5 scale) (6 analysts), mean target USD 1.8 (range 1–3).
- Total return with dividends: 1Y -85.0% vs S&P 500 +18.1%; 5Y -95.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.09, revenue estimate $24.6M.

## Analysts
Consensus Buy (mean 2.33 on a 1–5 scale), 6 analysts; mean target USD 1.8 (low 1, high 3).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-21 | BTIG | Target lowered | Buy | $4 → $2 |
| 2026-08-14 | Lake Street | Target lowered | Buy | $5 → $3 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-11-01) |
|---|---|---|
| Total return | -85.0% | -95.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -85.2% | -45.3% |
| Volatility (annualized) | 111.8% | 81.2% |
| Max drawdown | -92.0% (Oct 2025→Jun 2026) | -96.6% (Nov 2021→Jul 2026) |

## Peers (Diagnostics & Research)
MYGN (Myriad Genetics, Inc.) USD 4.35 +6.62% · FLGT (Fulgent Genetics, Inc.) USD 21.34 +1.33% · CSTL (Castle Biosciences, Inc.) USD 33.8 +2.80% · OPK (Opko Health, Inc.) USD 1.61 +21.97% · FRNM (Freenome, Inc.) USD 12.29 -2.81% · PSNL (Personalis, Inc.) USD 15.93 +0.50%

## More
Full page: https://nexqual.com/MDXH · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt